[{"address1": "One Cavendish Place", "address2": "4th Floor", "city": "London", "zip": "W1G 0QF", "country": "United Kingdom", "phone": "44 33 3023 7300", "website": "https://www.mereobiopharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.", "fullTimeEmployees": 33, "companyOfficers": [{"maxAge": 1, "name": "Dr. Denise Vera Scots-Knight Ph.D.", "age": 65, "title": "Co-Founder, CEO & Executive Director", "yearBorn": 1959, "fiscalYear": 2023, "totalPay": 890562, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Charles Edward Sermon", "age": 55, "title": "Co-Founder, General Counsel, Business Development & Company Secretary", "yearBorn": 1969, "fiscalYear": 2023, "totalPay": 625786, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Christine  Fox CPA", "age": 43, "title": "Chief Financial Officer", "yearBorn": 1981, "fiscalYear": 2023, "totalPay": 569768, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. John P. Richard M.B.A.", "age": 67, "title": "Co-Founder & Chief Business Officer", "yearBorn": 1957, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. John A. Lewicki Ph.D.", "age": 72, "title": "Chief Scientific Officer", "yearBorn": 1952, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jackie  Parkin", "age": 66, "title": "Senior VP & Therapeutic Head", "yearBorn": 1958, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Alexandra  Hughes-Wilson", "age": 53, "title": "Chief of Patient Access & Commercial Planning", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Suba  Krishnan", "age": 59, "title": "Senior Vice President of Clinical Development", "yearBorn": 1965, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bo  Kara", "title": "Senior VP and Head of Pharmaceutical Development & CMC", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 2.5, "open": 2.52, "dayLow": 2.51, "dayHigh": 2.66, "regularMarketPreviousClose": 2.5, "regularMarketOpen": 2.52, "regularMarketDayLow": 2.51, "regularMarketDayHigh": 2.66, "payoutRatio": 0.0, "beta": 0.979, "forwardPE": -87.33333, "volume": 682029, "regularMarketVolume": 682029, "averageVolume": 1285960, "averageVolume10days": 1493770, "averageDailyVolume10Day": 1493770, "bid": 0.0, "ask": 0.0, "bidSize": 0, "askSize": 0, "marketCap": 406482496, "fiftyTwoWeekLow": 2.25, "fiftyTwoWeekHigh": 5.02, "priceToSalesTrailing12Months": 406.48248, "fiftyDayAverage": 2.9276, "twoHundredDayAverage": 3.714925, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 1955324800, "profitMargins": 0.0, "floatShares": 505920599, "sharesOutstanding": 155146000, "sharesShort": 6360249, "sharesShortPriorMonth": 6820377, "sharesShortPreviousMonthDate": 1738281600, "dateShortInterest": 1740700800, "sharesPercentSharesOut": 0.040999997, "heldPercentInsiders": 0.01017, "heldPercentInstitutions": 0.7431, "shortRatio": 5.65, "shortPercentOfFloat": 0.048600003, "impliedSharesOutstanding": 140243008, "bookValue": 0.47, "priceToBook": 5.5744677, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -45316000, "trailingEps": -0.3, "forwardEps": -0.03, "enterpriseToRevenue": 1955.325, "enterpriseToEbitda": -52.175, "52WeekChange": -0.15210354, "SandP52WeekChange": 0.09506309, "quoteType": "EQUITY", "currentPrice": 2.62, "targetHighPrice": 10.638435, "targetLowPrice": 6.383061, "targetMeanPrice": 7.884548, "targetMedianPrice": 7.4216824, "recommendationMean": 1.14286, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 7, "totalCash": 80522000, "totalCashPerShare": 0.104, "ebitda": -37476000, "totalDebt": 6681000, "quickRatio": 5.834, "currentRatio": 6.104, "totalRevenue": 1000000, "debtToEquity": 9.211, "revenuePerShare": 0.007, "returnOnAssets": -0.3065, "returnOnEquity": -0.62112, "grossProfits": 1273000, "freeCashflow": -20088750, "operatingCashflow": -30203000, "grossMargins": 1.273, "ebitdaMargins": 0.0, "operatingMargins": -38.066, "financialCurrency": "USD", "symbol": "MREO", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "longName": "Mereo BioPharma Group plc", "marketState": "CLOSED", "corporateActions": [], "postMarketTime": 1741993903, "regularMarketTime": 1741982400, "exchange": "NCM", "messageBoardId": "finmb_307970474", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1556112600000, "postMarketChangePercent": 2.29008, "postMarketPrice": 2.68, "postMarketChange": 0.0600002, "regularMarketChange": 0.119999886, "regularMarketDayRange": "2.51 - 2.66", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 1285960, "fiftyTwoWeekLowChange": 0.3699999, "fiftyTwoWeekLowChangePercent": 0.16444439, "fiftyTwoWeekRange": "2.25 - 5.02", "fiftyTwoWeekHighChange": -2.4, "fiftyTwoWeekHighChangePercent": -0.47808766, "fiftyTwoWeekChangePercent": -15.210354, "earningsTimestampStart": 1731414600, "earningsTimestampEnd": 1731414600, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -0.3, "epsForward": -0.03, "epsCurrentYear": -0.04517, "priceEpsCurrentYear": -58.003094, "fiftyDayAverageChange": -0.30760002, "fiftyDayAverageChangePercent": -0.10506901, "twoHundredDayAverageChange": -1.0949252, "twoHundredDayAverageChangePercent": -0.2947368, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.1 - Strong Buy", "cryptoTradeable": false, "shortName": "Mereo BioPharma Group plc", "regularMarketChangePercent": 4.7999954, "regularMarketPrice": 2.62, "displayName": "Mereo BioPharma", "trailingPegRatio": null, "__fetch_time": "2025-03-15"}]